

XEUROPEAN CURRICULUM VITAE FORMAT



PERSONAL INFORMATION



LORENZO GERRATANA, MD

Fellow, Medical Oncology - University of Udine, Udine (UD); Italy

Affiliated Researcher, Liquid Biopsy Laboratory - Northwestern University, Chicago (IL); USA

☎ +39 0434 659253

✉ lorenzo.gerratana@uniud.it

📄 lgerratana

📅 Date of birth: 07.04.1986

☎ +1 (312) 838 8685

✉ lorenzo.gerratana@northwestern.edu

🐦 @LGerratana

📍 Place of birth: Udine (UD); Italy

WORK EXPERIENCE

- Dates (from – to) •
- Name and address of employer •
- Type of business or sector •
- Occupation or position held •
- Main activities and responsibilities •

September 2018 – present

Department of Medicine-Hematology and Oncology, Northwestern University, Chicago (IL); USA
Affiliated Researcher, Liquid Biopsy Laboratory

September 2017 – August 2018

Department of Medicine-Hematology and Oncology, Northwestern University, Chicago (IL); USA
Visiting Research Scholar, Liquid Biopsy Laboratory

June 2017 – present

Department of Clinical Oncology - CRO Aviano National Cancer Institute, Aviano (PN); Italy
Fellow, Medical Oncology

February 2015 – present

Department of Oncology - ASUI Udine SMM University Hospital, Udine (UD); Italy
Fellow, Medical Oncology

January 2014 – January 2015

Department of Medicine (DAME) - University of Udine, Udine (UD); Italy
Research Fellow, Molecular Biology and DNA Repair Laboratory

August 2012 – January 2015

Department of Medicine - Città di Udine Hospital, Udine (UD); Italy
Physician, Inpatient Urgent Care Medicine

July 2012 – June 2013

Department of Oncology - ASUI Udine SMM University Hospital, Udine (UD); Italy
Intern Physician, Medical Oncology

April 2016

ESMO Fellowship - Second University of Naples, Naples (NA); Italy
Translational Research Unit Visit

January 2014 – January 2015 (not completed)

Department of Medicine (DAME) - University of Udine, Udine (UD); Italy
PhD course in Biomedical Sciences and Biotechnology

November 2012

Institute of Genetics - University of Udine, Udine (UD); Italy
Practical Training on breast cancer molecular characterization

EDUCATION AND TRAINING

- Dates (from – to) •
- Name and type of organization •
- Subjects/occupational skills covered •
- Title of qualification awarded •
- Level in national classification •

September 2005 - 8 March 2012
 Medical School - University of Udine, Udine (UD); Italy
 Doctor of Medicine

September 2009 - March 2012
 Department of Oncology - ASUI Udine SMM University Hospital, Udine (UD); Italy
 Medical student Internship

February 2008 - March 2008
 Molecular Biology and Immunology section - University of Udine, Udine (UD); Italy
 Practical Training on regulatory T cells (Tregs) and immune regulation

September 2000 – July 2005
 Uccellis Classical European Lyceum, Udine (UD); Italy
 Baccalaureate, A levels, Classical Studies

LICENSES AND CERTIFICATIONS

Title of qualification awarded •
 Date •
 Name and type of organization •

Biomedical Research and Good Clinical Practice Training Certificate
 ▪ October 2017 - The Collaborative Institutional Training Initiative (CITI Program)
 ▪ March 2015 - TransCelerate Bio Pharma

Basic Life Support and Defibrillator Training Certificate
 ▪ December 2015 - University Hospital of Udine
 ▪ October 2013 - Italian Resuscitation Council
 ▪ October 2008 - Associazione Nazionale Medici Cardiologi Ospedalieri

Board certification
 ▪ July 2012 - Italian Board of Medicine

Certificate in Advanced English
 ▪ August 2004 - University of Cambridge

MOTHER TONGUE

ITALIAN

OTHER LANGUAGES

A1/A2: Basic user •
 B1/B2: Independent user •
 C1/C2 Proficient user •

ENGLISH, GERMAN

		English	German
Understanding	Listening	C1	B2
	Reading	C1	B2
Speaking	Spoken interaction	C1	B1
	Spoken production	C1	B1
Writing		C1	B1

SOCIAL SKILLS AND COMPETENCES

Living and working with other people, in multicultural environments, in positions where communication is important and situations where teamwork is essential

- Communication and care management in both inpatient and outpatient settings
- Speaking in public conferences and project presentations
- Ability to work and communicate in a multicultural environment
- Ability to work and collaborate in multidisciplinary teams
- Capability to communicate with both basic and clinical researchers and ability to work and collaborate in translational research groups.

ORGANIZATIONAL SKILLS AND COMPETENCES

Coordination and administration of people, projects and budgets; at work

- Design and coordination of clinical and basic research projects
- Development and writing of projects for grant application and research funding
- Good experience in project and team management
- Involved in training and tutoring of undergraduate students

**ARTISTIC SKILLS
AND COMPETENCES**

Music, writing, design, etc.

**DIGITAL SKILLS
AND COMPETENCES**

- Basic user •
- Independent user •
- Proficient user •

- Coordination and requirements verification of the fellows in Medical Oncology during the 2017 Joint Commission International accreditation of the ASUI Udine SMM University Hospital (Academic Teaching Hospital)
- Part of the IRCCS CRO Aviano National Cancer Institute writing committee for the breast cancer Diagnostic and Therapeutic integrated care pathway
- Computer graphics (raster and vector)
- HTML and PHP programming
- Desktop publishing

Information processing	Proficient user	
Communication	Proficient user	
Content creation	Proficient user	
Safety	Proficient user	
Problem solving	Proficient user	
Operating Systems	Mac OS [from 7 to 10.13]	Advanced
	Windows OS [from XP to 10]	Advanced
	Linux/Unix CLI	Basic
Applications	Apple Pages	Advanced
	Apple Keynote	Advanced
	Microsoft Office	Advanced
	Adobe Photoshop CC2015	Good
	Adobe InDesign CC2015	Basic
	Adobe Illustrator CC2015	Basic
	Adobe Acrobat DC2015	Advanced
	FileMaker Pro Advanced 14	Advanced
	LI-COR Image Studio	Good
	STATA 14	Good
	JMP 13	Good
	SAS 9.2	Good
	SPSS 23	Basic
	R 3.5.1	Basic
	OsiriX 8	Good
Celltracks Analyzer II Software 2.6	Basic	
DEPArray CellBrowser	Basic	
REDCap 7.4.23	Basic	

**OTHER SKILLS
AND COMPETENCES**

Competences not mentioned above.

- Clinical Database design (both as local solution and server-side)
- Survival analysis (e.g. Cox regression, log-rank test and Kaplan–Meier estimator)
- Association analysis
- Receiver Operating Characteristic Curve analysis
- Propensity score matching
- K nearest neighbor (KNN) machine learning algorithm
- Cancer cell culture
- Western blotting
- Immunofluorescence assay
- MTS colorimetric cell viability assay
- RNA Extraction
- Characterization and sorting of Circulating Tumor Cells through DEPArray technology

PROFESSIONAL MEMBERSHIPS

- Sorting of Circulating Tumor Cells through Parsortix technology

American Association for Cancer Research
Associate Member

American Society of Clinical Oncology
In training Member

European Society for Medical Oncology
Member

Associazione Italiana di Oncologia Medica
Active Member

HONORS AND AWARDS

University of Udine International Mobility Scholarship 2017
Extra-European postgraduate research and medical training

Breast Journal Club 2017
Best scientific study by an Italian Medical Trainee

Back from San Antonio 2017
Young oncologist international publication

AWARDED GRANTS AND RESEARCH APPLICATIONS

- Grant title •
- Role •
- Call •
- Funding Institution •

Exploring the underlying resistance mechanisms of hormone receptor positive metastatic breast cancer through longitudinal ctDNA assessments. The ACCURATE Project

Role: PI

Call: Intramural Cancer Specific Grant 2018

Funding Institution: IRCCS CRO Aviano National Cancer Institute

Design of a multi-parametric data analysis and management platform
The SENECA Project (SEarch, iNtEgrate, extraCt and Analyze)

Role: Co-PI

Call: Intramural Task Force Grant 2018

Funding Institution: IRCCS CRO Aviano National Cancer Institute

INVITED PRESENTATIONS AT CONFERENCES

- Event name •
- Dates (from – to) •
- Presentation title •

State of the art of liquid biopsy at CRO Aviano National Cancer Institute – 19.11.2018

Liquid biopsy in breast cancer patients: Clinical utility and possible integration with the decisional algorithm

CELLSEARCH® DEPAArray™ user meeting 2018 - 18.09.2018

Not all CTCs are created equal: moving from enumeration to characterization

AIOM post ASCO review - Updates and news from the Annual Meeting in Chicago - 17.06.2017
Breast cancer poster review

First national meeting on the treatment of elderly patients with breast cancer - 07.04.2017

Patient with HR+ HER2- tumor: beyond the endocrine therapy lines

Patient with HER2+ tumor

Focus sul carcinoma mammario XIV - 10.02.2017

Disseminating Research Findings

Back from San Antonio 2017 - 13.01.2017

Analyzing the needle in the haystack, Characterizing Circulating Tumor Cells in Breast cancer

HER2 e tumore mammario: prospettive per la terapia personalizzata - 02.12.2016

A “vision for HER2 future” Current therapeutic algorithm and future perspectives

Italian Breast Group (GIM) Annual Meeting - 10.09.2016

Multimodal BRCAness Assessment in tRiple negative Breast CANcer, The BARBiCAN Trial

EXPERIENCE IN CLINICAL TRIALS

- Study title
- Protocol code
- Role

Focus sul carcinoma mammario XIII - 18.02.2016

Scraping under the surface. Characterizing Circulating tumor cells and Exosomes in Breast cancer

Attualità in Senologia - 05.11.2015

(Seeking a) Gold standard therapy in BRCA mutated breast cancer

Italian Breast Group (GIM) Annual Meeting - 30.06.2015

BReAst CancEr Real world cohort in Neoadjuvant setting, The NeoBraCeR Study

Monitoring luminal breast cancer through the evaluation of mutational and epigenetic alterations of Circulating ESR1 DNA

Protocol: MAGNETIC.1

Role: Co-Investigator

An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination with Letrozole for the Treatment of Men and Pre/Postmenopausal Women with Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease

Protocol: NCT02941926 - COMPLEMENT-1

Role: Sub-investigator

Open Label, Multinational, Multicenter, Real World Treatment Study of Single Agent AZD9291 for Patients with Advanced/Metastatic Epidermal Growth Factor Receptor (EGFR) T790M Mutation-Positive Non-Small Cell Lung Cancer (NSCLC) Who Have Received Prior Therapy with an EGFR Tyrosine Kinase Inhibitor (EGFR-TKI)

Protocol: ASTRIS

Role: Sub-investigator

A Phase 2, randomized, open-label, multicenter study to assess safety and efficacy of nab-paclitaxel (ABI-007) with epigenetic modifying therapy of CC-486, and nab-paclitaxel monotherapy as second-line treatment in subjects with advanced nonsquamous non-small cell lung cancer (NSCLC): ABOUND.2L

Protocol: ABOUND.2L

Role: Sub-investigator

A Randomized-Controlled Three-arm Phase II Study of Lurbinectedin (PM01183) Alone or In Combination with Gemcitabine and a control arm with Docetaxel as Second-Line Treatment in Unresectable Non-Small Cell Lung Cancer (NSCLC) Patients

Role: Sub-investigator

A randomized open-label phase 3 trial comparing bevacizumab + erlotinib vs erlotinib alone as first line treatment of patients with EGFR mutated advanced non squamous non small cell lung cancer

Protocol: 2015-002235-17 - BEVERLY

Role: Sub-investigator

A Phase 2, Multicenter, Open-label Study to Assess the Efficacy and Safety of Enzalutamide with Trastuzumab in Subjects with HER2+ AR+ Metastatic or Locally Advanced Breast Cancer

Role: Sub-investigator

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple- Negative Breast Cancer (FRIDA)

Protocol: FRIDA

Role: Sub-investigator

A Phase III randomized, double-blind, placebo-controlled study of LEE011 or placebo in combination with tamoxifen and goserelin or a non-steroidal aromatase inhibitor (NSAI) and goserelin for the treatment of premenopausal women with hormone receptor positive, HER2-negative, advanced breast cancer

Protocol: MONALEESA 7

Role: Sub-investigator

A Phase II Single Arm Trial Evaluating the Efficacy and Safety of Eribulin in Combination With Bevacizumab for 2-Line Treatment of HER 2-Negative Metastatic Breast Cancer Progressing After 1-Line Therapy With Bevacizumab and Paclitaxel

Protocol: GIM11 - BERGI

Role: Sub-investigator

Fulvestrant followed by everolimus plus exemestane vs exemestane and everolimus followed by fulvestrant in postmenopausal women with hormone receptor positive (HR+) and human epidermal growth factor receptor type 2 negative (HER2-) locally advanced (LABC) or metastatic breast cancer (MBC) previously treated with non-steroidal aromatase inhibitors (NSAI): a multicentre, phase III trial.

Protocol: GIM16-FEVEX

Role: Sub-investigator

Adjuvant treatment for high-risk triple negative breast cancer patients with the anti-PD-L1 antibody avelumab: a phase III randomized trial.

Protocol: ABRAVE

Role: Sub-investigator

A randomised, multicentre, open-label Phase II trial investigating activity of chemotherapy and lapatinib and trastuzumab in patients with HER2-positive metastatic breast cancer (MBC) refractory to anti HER2 therapies

Protocol: GIM12 - TYPHER

Role: Sub-investigator

Evaluation of medical treatments (chemotherapy, hormonal therapy and biological therapies) in metastatic breast cancer patients according to biologic subtype and line of treatment.

Protocol: GIM14-BIO-META

Role: Sub-investigator

A phase III, double-blind, placebo-controlled, randomized study of tasisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal women with estrogen receptor-positive and HER2-negative locally advanced or metastatic breast cancer who have disease recurrence or progression during or after aromatase inhibitor therapy

Protocol: GO29058 - SANDPIPER

Role: Sub-investigator

Neo-Adjuvant study with the PDL1-directed antibody in Triple Negative Locally Advanced Breast Cancer undergoing treatment with nab-paclitaxel and carboplatin

Protocol: FM-14-B02 - NeoTRIPaPDL

Role: Sub-investigator

PERtuzumab-trastuzumab plus IETrozole in endocrine Sensitive breast cancer: a phase II neoAdjuvant study"

Protocol: PER-ELISA

Role: Sub-investigator

PEER REVIEWER

Source:

Publons - last update: 22.12.2018

Performed 25 reviews for journals including Clinical Cancer Research and Cancer Research; placing in the 90th percentile for verified review contributions on Publons up until December 2018.

- 1 Clinical Cancer Research
- 3 Cancer Research
- 1 Cancer Treatment Reviews
- 2 Therapeutic Advances in Medical Oncology
- 4 International Journal of Molecular Sciences
- 1 Expert Review of Gastroenterology & Hepatology
- 5 The Breast
- 2 OncoTargets and Therapy
- 1 Future Oncology
- 1 Patient Preference and Adherence
- 4 Medical Sciences

GRANT REVIEWER

- Breast Cancer Now Grants, Grant reviewer, 2018

CHAPTERS IN BOOKS

Basile D, Gerratana L, Pelizzari G, Puglisi F. Trattamento primario del carcinoma mammario operabile e del carcinoma mammario localmente avanzato non operabile. In: Il Pensiero Scientifico Editore, ed. *Il Carcinoma Della Mammella*. 1st ed. ; 2018:195-209.

BIBLIOMETRICS

Source:
Scopus - last update: 16.12.2018

Scopus Author ID: 55762374700
ResearcherID: F-1990-2014
ORCID: 0000-0002-8313-4834

h-index: 8

Citations: 226 by 195 documents

Documents: 31

JOURNAL ARTICLES

Source:
Pubmed - last update: 16.12.2018

Cristofanilli M, Pierga J-Y, Reuben J, Rademaker A, Davis A, Peeters D, Fehm T, Nole F, Gisbert-Criado R, Mavroudis D, Grisanti S, Giuliano M, Garcia-Saenz J, Stebbing J, Caldas C, Gazzaniga P, Manso L, Zamarchi R, Lascoiti AF de, Mattos-Arruda L De, Ignatiadis M, Cabel L, Laere S van, Meier-Stiegen F, Sandri M-T, Jose V, Politaki E, Consoli F, Generali D, Cappelletti MR, Diaz-Rubio E, Krell J, Dawson S-J, Raimondi C, Rutten A, Janni W, Munzone E, Caranana V, Agelaki S, Almici C, Dirix L, Solomayer E-F, Zorzino L, Darrigues L, Reis-Filho J, Gerratana L, Michiels S, Bidard FC, Pantel K. The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): recommendations by international expert panel. *Crit Rev Oncol / Hematol*. 2018. doi:10.1016/j.critrevonc.2018.12.004.

Fanotto V, Fornaro L, Bordonaro R, Rosati G, Rimassa L, Di Donato S, Santini D, Tomasello G, Leone F, Silvestris N, Stragliotto S, Scartozzi M, Giampieri R, Nichetti F, Antonuzzo L, Cinieri S, Avallone A, Pellegrino A, Melisi D, Vasile E, Gerratana L, Aprile G. Second-line treatment efficacy and toxicity in older vs. non-older patients with advanced gastric cancer: A multicentre real-world study. *J Geriatr Oncol*. December 2018. doi:10.1016/j.jgo.2018.11.009.

Basile D, Parnofiello A, Vitale M, Cortiula F, Gerratana L, Fanotto V, Lisanti C, Pelizzari G, Ongaro E, Bartoletti M, Garattini S, Andreotti V, Bacco A, Iacono D, Bonotto M, Casagrande M, Ermacora P, Puglisi F, Pella N, Fasola G, Aprile G, Cardellino G. The IMPACT study: early loss of skeletal muscle mass in advanced Pancreatic Cancer patients. *J Cachexia Sarcopenia Muscle*. 2018;(Accepted for publication).

Liu X, Taftaf R, Kawaguchi M, Chang Y-F, Chen W, Entenberg D, Zhang Y, Gerratana L, Huang S, Patel DB, Tsui E, Adorno-Cruz V, Chirieleison SM, Cao Y, Harney AS, Patel S, Patsialou A, Shen Y, Avril S, Gilmore HL, Lathia JD, Abbott DW, Cristofanilli M, Condeelis JS, Liu H. Homophilic CD44 interactions mediate tumor cell aggregation and polyclonal metastasis in patient-derived breast cancer models. *Cancer Discov*. October 2018;CD-18-0065. doi:10.1158/2159-8290.CD-18-0065.

Pelizzari G, Gerratana L, Basile D, Fanotto V, Bartoletti M, Liguori A, Fontanella C, Spazzapan S, Puglisi F. Post-neoadjuvant strategies in breast cancer: From risk assessment to treatment escalation. *Cancer Treat Rev*. 2019;72(0):7-14. doi:10.1016/j.ctrv.2018.10.014.

 *Corresponding author*

Mio C, Gerratana L, Bolis M, Caponnetto F, Zanello A, Barbina M, Di Loreto C, Garattini E, Damante G, Puglisi F. BET proteins regulate homologous recombination-mediated DNA repair: BRCAness and implications for cancer therapy. *Int J Cancer*. December 2018. doi:10.1002/ijc.31898.

 *Co-first author; Corresponding author*

Cortiula F, De Maglio G, Cangì MG, Gerratana L, Lisanti C, Bonura S, Fasola G, Follador A. Third-generation tyrosine kinase inhibitor in the treatment of Epidermal Growth Factor Receptor mutated squamous cell lung cancer: a tailored therapy approach. *Ann Transl Med*. 2018;(Accepted for publication). doi:10.21037/atm.2018.12.42.

De Carlo E, Gerratana L, De Maglio G, Buoro V, Cortiula F, Gurrieri L, Isola M, Fasola G, Puglisi F, Pizzolitto S, Rizzato S. Defining a prognostic score based on O6-methylguanine-DNA methyltransferase cut-off methylation level determined by pyrosequencing in patients with glioblastoma multiforme. *J Neurooncol*. August 2018. doi:10.1007/s11060-018-2981-7.

 *Corresponding author*

Bozza C, Gerratana L, Basile D, Vitale MG, Bartoletti M, Agostinetto E, Russo S, Follador A, De Carlo E, Pella N, Sottile R, Fasola G, Puglisi F. Use and perception of complementary and alternative medicine among cancer patients: the CAMEO-PRO study. *J Cancer Res Clin Oncol*. 2018;144(10):2029-2047. doi:10.1007/s00432-018-2709-2.

Gerratana L, Basile D, Buono G, De Placido S, Giuliano M, Minichillo S, Coinu A, Martorana F, De Santo I, Del Mastro L, De Laurentiis M, Puglisi F, Arpino G. Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype. *Cancer Treat Rev*. 2018;68:102-110. doi:10.1016/j.ctrv.2018.06.005.

Iacono D, Cinausero M, Gerratana L, Angione V, Scott CA, De Maglio G, Pizzolitto S, Di Loreto C, Puglisi F, Fasola G, Minisini AM. Tumour-infiltrating lymphocytes, programmed death ligand 1 and cyclooxygenase-2 expression in skin melanoma of elderly patients. *Melanoma Res.* 2018;28(6):547-554. doi:10.1097/CMR.0000000000000462.

Bonotto M, Basile D, Gerratana L, Pelizzari G, Bartoletti M, Vitale MG, Fanotto V, Lisanti C, Mansutti M, Minisini AM, Aprile G, De Laurentiis M, Montemurro F, Del Mastro L, Puglisi F. Controversies in monitoring metastatic breast cancer during systemic treatment. Results of a GIM (Gruppo Italiano Mammella) survey. *The Breast.* 2018;40:45-52. doi:10.1016/j.breast.2018.04.011.

Gurrieri L, De Carlo E, Gerratana L, De Maglio G, Macerelli M, Pisa FE, Masiero E, Aprile G, Follador A, Puglisi F, Fasola G, Rizzato S, Pizzolitto S. MGMT pyrosequencing-based cut-off methylation level and clinical outcome in patients with glioblastoma multiforme. *Futur Oncol.* 2018;14(8):699-707. doi:10.2217/fon-2017-0437.

 *Corresponding author*

Ongaro E, Gerratana L, Cinausero M, Pelizzari G, Poletto E, Giangreco M, Andreetta C, Pizzolitto S, Di Loreto C, Minisini AM, Mansutti M, Russo S, Fasola G, Puglisi F. Comparison of primary breast cancer and paired metastases: biomarkers discordance influence on outcome and therapy. *Futur Oncol.* 2018;14(9):849-859. doi:10.2217/fon-2017-0384.

 *Corresponding author*

De Angelis C, Di Maio M, Crispo A, Giuliano M, Schettini F, Bonotto M, Gerratana L, Iacono D, Cinausero M, Riccardi F, Ciancia G, De Laurentiis M, Puglisi F, De Placido S, Arpino G. Luminal-like HER2-negative stage IA breast cancer: a multicenter retrospective study on long-term outcome with propensity score analysis. *Oncotarget.* 2017;8(68). doi:10.18632/oncotarget.22643.

Basile D, Cinausero M, Iacono D, Pelizzari G, Bonotto M, Vitale MG, Gerratana L, Puglisi F. Androgen receptor in estrogen receptor positive breast cancer: Beyond expression. *Cancer Treat Rev.* 2017;61:15-22. doi:10.1016/j.ctrv.2017.09.006.

 *Corresponding author*

Fornaro L, Fanotto V, Musettini G, Uccello M, Rimassa L, Vivaldi C, Fontanella C, Leone F, Giampieri R, Rosati G, Lencioni M, Santini D, Di Donato S, Tomasello G, Brunetti O, Pietrantonio F, Bergamo F, Scartozzi M, Avallone A, Lutrino SE, Melisi D, Antonuzzo L, Pellegrino A, Gerratana L, Cordio S, Vasile E, Aprile G. Selecting patients for gastrectomy in metastatic esophago-gastric cancer: clinics and pathology are not enough. *Futur Oncol.* 2017;13(25):2265-2275. doi:10.2217/fon-2017-0246.

Fanotto V, Uccello M, Pecora I, Rimassa L, Leone F, Rosati G, Santini D, Giampieri R, Di Donato S, Tomasello G, Silvestris N, Pietrantonio F, Battaglin F, Avallone A, Scartozzi M, Lutrino ES, Melisi D, Antonuzzo L, Pellegrino A, Ferrari L, Bordonaro R, Vivaldi C, Gerratana L, Bozzarelli S, Filippi R, Bilancia D, Russano M, Aprile G. Outcomes of Advanced Gastric Cancer Patients Treated with at Least Three Lines of Systemic Chemotherapy. *Oncologist.* 2017;22(12):1463-1469. doi:10.1634/theoncologist.2017-0158.

Cinausero M, Gerratana L, De Carlo E, Iacono D, Bonotto M, Fanotto V, Buoro V, Basile D, Vitale MG, Rihawi K, Fasola G, Puglisi F. Determinants of Last-line Treatment in Metastatic Breast Cancer. *Clin Breast Cancer.* 2018;18(3):205-213. doi:10.1016/j.clbc.2017.07.008.

Gerratana L, Bonotto M, Bozza C, Ongaro E, Fanotto V, Pelizzari G, Puglisi F. Pertuzumab and breast cancer: another piece in the anti-HER2 puzzle. *Expert Opin Biol Ther.* 2017;17(3):365-374. doi:10.1080/14712598.2017.1282944.

Bonotto M, Gerratana L, Di Maio M, De Angelis C, Cinausero M, Moroso S, Milano M, Stanzione B, Gargiulo P, Iacono D, Minisini AM, Mansutti M, Fasola G, De Placido S, Arpino G, Puglisi F. Chemotherapy versus endocrine therapy as first-line treatment in patients with luminal-like HER2-negative metastatic breast cancer: A propensity score analysis. *The Breast.* 2017;31:114-120. doi:10.1016/j.breast.2016.10.021.

Gerratana L, De Maglio G, De Pellegrin A, Follador A, Rihawi K, Pizzolitto S, Puglisi F, Fasola G. Real-time tests of multiple genome alterations take the first steps into the clinic: a learning example. *Onco Targets Ther.* 2016;Volume 9:5399-5404. doi:10.2147/OTT.S104748.

Puglisi F, Agostinetti E, Gerratana L, Bozza C, Cancian M, Iannelli E, Ratti G, Cinieri S, Numico G. Caring for cancer survivors: perspectives of oncologists, general practitioners and patients in Italy. *Futur Oncol.* 2017;13(3):233-248. doi:10.2217/fon-2016-0383.

 *Corresponding author*

Gerratana L, Fanotto V, Pelizzari G, Agostinetto E, Puglisi F. Do platinum salts fit all triple negative breast cancers? *Cancer Treat Rev.* 2016;48:34-41. doi:10.1016/j.ctrv.2016.06.004.

Bulfony M, Gerratana L, Del Ben F, Marzinotto S, Sorrentino M, Turetta M, Scoles G, Toffoletto B, Isola M, Beltrami CA, Di Loreto C, Beltrami AP, Puglisi F, Cesselli D. In patients with metastatic breast cancer the identification of circulating tumor cells in epithelial-to-mesenchymal transition is associated with a poor prognosis. *Breast Cancer Res.* 2016;18(1):30. doi:10.1186/s13058-016-0687-3.

📖 *Co-first author*

Bonotto M, Gerratana L, Iacono D, Minisini AM, Rihawi K, Fasola G, Puglisi F. Treatment of Metastatic Breast Cancer in a Real-World Scenario: Is Progression-Free Survival With First Line Predictive of Benefit From Second and Later Lines? *Oncologist.* 2015;20(7):719-724. doi:10.1634/theoncologist.2015-0002.

Bozza C, Agostinetto E, Gerratana L, Puglisi F. Complementary and alternative medicine in oncology. *Recenti Prog Med.* 2015;106(12):601-607. doi:10.1701/2094.22648.

Gerratana L, Fanotto V, Bonotto M, Bolzonello S, Minisini AM, Fasola G, Puglisi F. Pattern of metastasis and outcome in patients with breast cancer. *Clin Exp Metastasis.* 2015;32(2):125-133. doi:10.1007/s10585-015-9697-2.

Bonotto M, Gerratana L, Poletto E, Driol P, Giangreco M, Russo S, Minisini AM, Andreetta C, Mansutti M, Pisa FE, Fasola G, Puglisi F. Measures of Outcome in Metastatic Breast Cancer: Insights From a Real-World Scenario. *Oncologist.* 2014;19(6):608-615. doi:10.1634/theoncologist.2014-0002.

📖 *Co-first author*

Russo S, Cinausero M, Gerratana L, Bozza C, Iacono D, Driol P, Deroma L, Sottile R, Fasola G, Puglisi F. Factors affecting patient's perception of anticancer treatments side-effects: an observational study. *Expert Opin Drug Saf.* 2014;13(2):139-150. doi:10.1517/14740338.2013.830710.

Minisini AM, Moroso S, Gerratana L, Giangreco M, Iacono D, Poletto E, Guardascione M, Fontanella C, Fasola G, Puglisi F. Risk factors and survival outcomes in patients with brain metastases from breast cancer. *Clin Exp Metastasis.* 2013;30(8):951-956. doi:10.1007/s10585-013-9594-5.

CONFERENCE PROCEEDINGS

- Meeting abstracts •
- Poster presentations •
- Oral communications •

Pelizzari G, Gerratana L, Basile D, Zago S, Vitale MG, Bartoletti M, Lisanti C, Fanotto V, Corvaja C, Bortot L, Liguori A, Cinausero M, Russo S, Andreetta C, Bonotto M, Mansutti M, Minisini AM, Curcio F, Fasola G, Puglisi F. 302PA risk score integrating lymphocytes ratios (LRs) and lactate dehydrogenase (LDH) levels to predict prognosis in metastatic breast cancer (MBC) patients. *Ann Oncol.* 2018;29(suppl_8). doi:10.1093/annonc/mdy272.292.

📖 Poster presentation at the 2018 ESMO Annual Meeting.

Basile D, Garattini SK, Pelizzari G, Cortiula F, Gerratana L, Cattaneo M, Corvaja C, Parnofiello A, Andreotti VJ, Bertoli E, Lisanti C, Iacono D, Casagrande M, Cardellino GG, Miolo G, Pella N, Aprile G, Buonadonna A, Fasola G, Puglisi F. 540P Monocyte-to-lymphocyte ratio in metastatic colorectal cancer: Prognostic role evaluation and cut-off definition. *Ann Oncol.* 2018;29(suppl_8). doi:10.1093/annonc/mdy281.086.

📖 Poster presentation at the 2018 ESMO Annual Meeting.

Basile D, Lisanti C, Borghi M, Bartoletti M, Gerratana L, Bortot L, Pelizzari G, Corvaja C, Ongaro E, Garattini SK, Fanotto V, Parnofiello A, Cortiula F, Cattaneo M, Andreotti VJ, Bertoli E, Guardascione M, Miolo G, Puglisi F, Buonadonna A. 579P The SLICE study: The prognostic role of visceral fat in metastatic colorectal cancer. *Ann Oncol.* 2018;29(suppl_8). doi:10.1093/annonc/mdy281.125.

📖 Poster presentation at the 2018 ESMO Annual Meeting.

Zhang Q, Gerratana L, Flaum L, Shah AN, Helfand B, Zhang Y, Gradishar WJ, Platanius LC, Cristofanilli M. Dynamic changes of interleukin 2 (IL-2) and circulating tumor cells (CTCs) in patients with advanced breast cancer (BCa) after systemic therapies. *J Clin Oncol.* 2018;36(15_suppl):1090-1090. doi:10.1200/JCO.2018.36.15_suppl.1090.

📖 Poster presentation at the 2018 ASCO Annual Meeting.

Gerratana L, Bulfoni M, Basile D, Pelizzari G, Bonotto M, Beltrami AP, Zhang Q, Minisini AM, Di Loreto C, Fasola G, Cristofanilli M, Cesselli D, Puglisi F. Integration of lymphocyte ratios (LRs) and circulating tumor cells (CTCs) characterization: The interplay between immunity and metastatic breast cancer (MBC). *J Clin Oncol.* 2018;36(15_suppl):12039-12039. doi:10.1200/JCO.2018.36.15_suppl.12039.

📄 Poster presentation at the 2018 ASCO Annual Meeting.

Gerratana L, Zhang Q, Davis AA, Zhang Y, Rossi G, Strickland K, Mu Z, Flaum LE, Santa-Maria CA, Yang H, Gradishar WJ, Platanius LC, Cristofanilli M. Circulating tumor cells enumeration (CTCs) and circulating tumor DNA (ctDNA): Clinical and molecular features of “rapidly progressing” stage IV disease (Stage IV prog). *J Clin Oncol.* 2018;36(15_suppl):12040-12040. doi:10.1200/JCO.2018.36.15_suppl.12040.

📄 Poster presentation at the 2018 ASCO Annual Meeting.

Pelizzari G, Gerratana L, Basile D, Vitale MG, Bartoletti M, Lisanti C, Fanotto V, Liguori A, Cinausero M, Bozza C, Poletto E, Pascoletti G, Russo S, Andreetta C, Bonotto M, Mansutti M, Minisini AM, Curcio F, Fasola G, Puglisi F. Prognostic role of alkaline phosphatase (ALP) and lactate dehydrogenase (LDH) in metastatic breast cancer (MBC) patients: First clues for cost-effective biomarkers. *J Clin Oncol.* 2018;36(15_suppl):e13079-e13079. doi:10.1200/JCO.2018.36.15_suppl.e13079.

📄 Online publication at the 2018 ASCO Annual Meeting.

Bozza C, Puglisi F, Gerratana L, Basile D, Vitale MG, Bartoletti M, Russo S, Pella N, Follador A, Mansutti M, Minisini AM, Cinausero M, Pelizzari G, Sacco CSP, Sottile R, Canciani G, Fasola G. Perception and opinions of health professionals of an Italian academic hospital about complementary and alternative medicine in oncology. *J Clin Oncol.* 2018;36(15_suppl):e18865-e18865. doi:10.1200/JCO.2018.36.15_suppl.e18865.

📄 Online publication at the 2018 ASCO Annual Meeting.

Bonotto M, Gerratana L, Pelizzari G, Basile D, Cinausero M, Vitale MG, Bertoli E, Bettini A, Bartoletti M, Buoro V, Poletto E, Pascoletti G, Russo S, Andreetta C, Minisini AM, Mansutti M, Fasola G, Puglisi F. Association of clinical factors and biological subtypes with different Ca15-3 levels in metastatic breast cancer. *J Clin Oncol.* 2018;36(15_suppl):e24014-e24014. doi:10.1200/JCO.2018.36.15_suppl.e24014.

📄 Online publication at the 2018 ASCO Annual Meeting.

Cinausero M, Galli G, Basile D, Martorana F, De Santo I, Perroud HA, Antone NZ, Campos Gomez S, Gerratana L, Minisini AM, Sant M, Folli S, Campos Gomez KA, Eniu AE, Cismaru A, Arpino G, Vigneri PG, Fasola G, Di Cosimo S, Puglisi F. Prognostic value of the interval between the last neoadjuvant chemotherapy (CT) administration and breast surgery: Preliminary data of the NeoBracer international observational study. *J Clin Oncol.* 2018;36(15_suppl):e12629-e12629. doi:10.1200/JCO.2018.36.15_suppl.e12629.

📄 Online publication at the 2018 ASCO Annual Meeting.

Gerratana L, Davis AA, Rossi G, Strickland K, Mu Z, Flaum L, Gradishar WJ, Santa-Maria C, Yang H, Cristofanilli M. Abstract 2646: The liquid biopsy network in advanced breast cancer (ABC): Benchmarking the prognostic role of circulating tumor DNA (ctDNA) to the goal standard circulating tumor cells (CTCs) enumeration. *Cancer Res.* 2018;78(13 Supplement):2646-2646. doi:10.1158/1538-7445.AM2018-2646.

📄 Poster presentation at the 2018 AACR Annual Meeting.

Zhang Q, Zhang Y, Flaum LE, Helfand B, Gerratana L, Gradishar W, Platanius L, Cristofanilli M, Cristofanilli M. Abstract LB-370: A novel ex vivo culture workflow to enrich and expand circulating tumor cells (CTCs) from patients with stage III/IV breast cancer (BCa). *Cancer Res.* 2018;78(13 Supplement):LB-370-LB-370. doi:10.1158/1538-7445.AM2018-LB-370.

📄 Late-Breaking Poster Session at the 2018 AACR Annual Meeting.

Zhang Q, Gerratana L, Flaum L, Zhang Y, Gradishar W, Platanius L, Cristofanilli M. Abstract 1597: Increased circulating tumor cell (CTC) after systemic therapy is associated with younger age in stage III/IV breast cancer patients. *Cancer Res.* 2018;78(13 Supplement):1597-1597. doi:10.1158/1538-7445.AM2018-1597.

📄 Poster presentation at the 2018 AACR Annual Meeting.

Zhang Q, Zhang Y, Flaum L, Gerratana L, Gradishar W, Platanius L, Cristofanilli M. Abstract 5195: Increased circulating tumor cell (CTC) clusters are associated with significantly higher levels of HER2 expression and metastasis in stage III/IV breast cancer. *Cancer Res.* 2018;78(13 Supplement):5195-5195. doi:10.1158/1538-7445.AM2018-5195.

📄 Poster presentation at the 2018 AACR Annual Meeting.

- Gerratana L, Puglisi F, Damante G, Mio C. Abstract PD1-14: Induction of epigenetic BRCAness in BRCA1 wild-type triple negative breast cancer: BET inhibition as a therapeutic strategy. *Cancer Res.* 2018;78(4 Supplement):PD1-14-PD1-14. doi:10.1158/1538-7445.SABCS17-PD1-14.
 📄 Poster spotlight discussion at the 2017 San Antonio Breast Cancer Symposium
- Pelizzari G, Gerratana L, Cattaneo M, Cortiula F, Lisanti C, Bartoletti M, Giavarra M, Buoro V, De Carlo E, Macerelli M, Poletto E, Rossetto C, Rizzato S, Puglisi F, Fasola G, Follador A. First-Line Platinum-Based chemotherapy in elderly patients with NSCLC: determinants of choice and outcome. In: *XIII Congresso Nazionale FONICAP.* ; 2017.
 📄 Poster presentation at the 2017 FONICAP Annual Meeting.
- Basile D, Bacco A, Parnofiello A, Vitale M, Cortiula F, Garattini S, Gerratana L, Andreotti V, Lisanti C, Bartoletti M, Bonotto M, Fanotto V, Cattaneo, Iacono D, Ermacora P, Puglisi F, Aprile G, Pella N, Cardellino G, Fasola G. Early loss of skeletal muscle mass as prognostic factor in metastatic pancreatic cancer patients. In: *SINPE Annual Meeting.* ; 2017.
 📄 Oral communication at the 2017 SINPE Annual Meeting.
- D'Alonzo A, Bighin C, Puglisi F, Gerratana L, De Laurentis M, Fontana A, Pugliese P, Ferzi A, Montemurro F, Arpino G, Poggio F, Vaglica M, Dellepiane C, Blondeaux E, Benedetta C, Cognetti F, Garrone O, Turletti A, Pastorino S, Del Mastro L. C1*Trends in the choice of first line treatment for hormone - responsive (HR+), human epidermal growth factor receptor - 2 negative (HER2-) metastatic breast cancer (MBC) patients (pts): results of a multicentric Italian observational study. *Ann Oncol.* 2017;28(suppl_6). doi:10.1093/annonc/mdx424.
 📄 Oral communication at the 2017 AIOM Annual Meeting.
- Malfatti MC, Gerratana L, Di Loreto C, Puglisi F, Tell G. C41The APE1/NPM1 axis in triple negative breast cancer: prognostic and therapeutic implications. *Ann Oncol.* 2017;28(suppl_6). doi:10.1093/annonc/mdx424.040.
 📄 Poster presentation at the 2017 AIOM Annual Meeting.
- Gerratana L, Zago S, Basile D, Vitale MG, Pelizzari G, Bonotto M, Bozza C, Bartoletti M, Fanotto V, Lisanti C, Cinausero M, Barban S, Lera M, Venuti I, Mansutti M, Minisini AM, Fasola G, Curcio F, Puglisi F. C10Neutrophil-to-lymphocyte and lymphocyte-to-monocyte ratios in breast cancer. *Ann Oncol.* 2017;28(suppl_6):272. doi:10.1093/annonc/mdx424.009.
 📄 Poster presentation at the 2017 AIOM Annual Meeting.
- Vitale MG, Bonotto M, Gerratana L, Basile D, Bartoletti M, Pelizzari G, Fanotto V, Lisanti C, Bozza C, Cinausero M, Iacono D, Poletto E, Barban S, Mansutti I, Minisini AM, Russo S, Andreetta C, Mansutti M, Fasola G, Puglisi F. C18Strategy of monitoring metastatic breast cancer (M-MBC) in clinical practice: more or less intensive? *Ann Oncol.* 2017;28(suppl_6):98. doi:10.1093/annonc/mdx424.017.
 📄 Poster presentation at the 2017 AIOM Annual Meeting.
- Ongaro E, De Maglio G, Gerratana L, Bonotto M, Garattini SK, Basile D, Cattaneo M, Andreotti VJ, Cortiula F, Parnofiello A, Fanotto V, Pizzolitto S, Cardellino GG, Casagrande M, Ermacora P, Giovannoni M, Iacono D, Puglisi F, Aprile G, Pella N, Fasola G. A24Mutational status and metastatic pattern in a cohort Of ADvanced colorectal cancer patients: the ROAD study. *Ann Oncol.* 2017;28(suppl_6):96. doi:10.1093/annonc/mdx422.023.
 📄 Poster presentation at the 2017 AIOM Annual Meeting.
- Cinausero M, Galli G, Basile D, Gerratana L, Fasola G, De Braud F, Sant M, Paolini B, Puglisi F, Di Cosimo S. C15Time to surgery after neoadjuvant chemotherapy for early breast cancer. *Ann Oncol.* 2017;28(suppl_6). doi:10.1093/annonc/mdx424.014.
 📄 Poster presentation at the 2017 AIOM Annual Meeting.
- Iacono D, Basile D, Gerratana L, Vitale MG, Pelizzari G, Cinausero M, Poletto E, Puglisi F, Fasola G, Minisini AM. G2Prognostic role of disease extent and lymphocyte-monocyte ratio in advanced melanoma. *Ann Oncol.* 2017;28(suppl_6):271. doi:10.1093/annonc/mdx428.001.
 📄 Poster presentation at the 2017 AIOM Annual Meeting.
- Bettini A, Gerratana L, Pelizzari G, Bonotto M, Basile D, Vitale MG, Bozza C, Bartoletti M, Fanotto V, Lisanti C, Cinausero M, Mansutti M, Minisini AM, Fasola G, Puglisi F. C29Small luminal-like breast cancer: determinants of adjuvant chemotherapy use. *Ann Oncol.* 2017;28(suppl_6). doi:10.1093/annonc/mdx424.028.
 📄 Poster presentation at the 2017 AIOM Annual Meeting.

Bartoletti M, Gerratana L, Zago S, Basile D, Fanotto V, Vitale MG, Pelizzari G, Bonotto M, Bozza C, Lisanti C, Cinausero M, Barban S, Lera M, Venuti I, Mansutti M, Minisini AM, Fasola G, Curcio F, Puglisi F. C30Neutrophil-to-lymphocyte ratio in metastatic breast cancer patients: relationship with tumor characteristics and survival. *Ann Oncol.* 2017;28(suppl_6):95. doi:10.1093/annonc/mdx424.029.

📄 Poster presentation at the 2017 AIOM Annual Meeting.

Pelizzari G, Gerratana L, Cattaneo M, Cortiula F, Lisanti C, Bartoletti M, Giavarra M, Buoro V, De Carlo E, Macerelli M, Poletto E, Rossetto C, Rizzato S, Puglisi F, Fasola G. E25First-line platinum-based chemotherapy in elderly patients with NSCLC: determinants of therapeutic choice and outcome. *Ann Oncol.* 2017;28(suppl_6):95. doi:10.1093/annonc/mdx426.024.

📄 Poster presentation at the 2017 AIOM Annual Meeting.

Basile D, Parnofiello A, Vitale MG, Cortiula F, Garattini SK, Gerratana L, Andreotti VJ, Ongaro E, Lisanti C, Bartoletti M, Bonotto M, Fanotto V, Cattaneo M, Iacono D, Bacco A, Ermacora P, Puglisi F, Aprile G, Pella N, Cardellino GG, Fasola G. D18Early loss of skeletal muscle mass (LSMM) as prognostic factor in metastatic pancreatic cancer (PC) patients. *Ann Oncol.* 2017;28(suppl_6):79. doi:10.1093/annonc/mdx425.017.

📄 Poster presentation at the 2017 AIOM Annual Meeting.

Bonotto M, Basile D, Gerratana L, Pelizzari G, Bartoletti M, Vitale MG, Fanotto V, Lisanti C, Bozza C, Cinausero M, Andreetta C, Russo S, Mansutti M, Minisini AM, Merlini L, De Laurentiis M, Montemurro F, Fasola G, Del Mastro L, Puglisi F. C19Monitoring metastatic breast cancer (M-MBC) during treatment: a GIM (Gruppo Italiano Mammella) survey. *Ann Oncol.* 2017;28(suppl_6). doi:10.1093/annonc/mdx424.018.

📄 Poster presentation at the 2017 AIOM Annual Meeting.

Fanotto V, Uccello M, Fornaro L, Rimassa L, Leone F, Rosati G, Santini D, Giampieri R, Di Donato S, Tomasello G, Silvestris N, Peverelli G, Battaglin F, Avallone A, Scartozzi M, Cinieri S, Melisi D, Antonuzzo L, Pellegrino A, Gerratana L, Aprile G. D5Second-line treatment efficacy in elderly vs. non-elderly advanced gastric cancer patients: an Italian multicentre real-world study. *Ann Oncol.* 2017;28(suppl_6):vi45. doi:10.1093/annonc/mdx425.004.

📄 Poster presentation at the 2017 AIOM Annual Meeting.

Bozza C, Gerratana L, Basile D, De Carlo E, Cortiula F, Pella N, Vitale MG, Bartoletti M, Russo S, Bonotto M, Cinausero M, Fanotto V, Pelizzari G, Minisini AM, Andreetta C, Mansutti M, Iacono D, Sottile R, Fasola G, Puglisi F. T6Final results from CAMEO-PRO study: complementary and alternative medicine in oncology. physicians inform oncological patients. *Ann Oncol.* 2017;28(suppl_6):e21632-e21632. doi:10.1093/annonc/mdx436.005.

📄 Poster presentation at the 2017 AIOM Annual Meeting.

Cortiula F, Basile D, Gerratana L, Bonotto M, Ongaro E, Garattini SK, Fanotto V, Cattaneo M, Andreotti VJ, Parnofiello A, Cocconi R, Pecori D, Cardellino GG, Casagrande M, Ermacora P, Giovannoni M, Iacono D, Puglisi F, Aprile G, Pella N, Fasola G. T13Blood stream infection in cancer patients—device management and epidemiology: the BSIDE study. *Ann Oncol.* 2017;28(suppl_6). doi:10.1093/annonc/mdx436.012.

📄 Online publication at the 2017 AIOM Annual Meeting.

Gerratana L, Mio C, Franzoni A, Basile D, Damante G, Puglisi F. Induction of epigenetic BRCAness in homologous recombination-proficient triple negative breast cancer: BET inhibition as a new therapeutic approach. In: *ACC 2017 Annual Meeting.* ; 2017.

📄 Poster presentation at the 2017 ACC Annual Meeting.

Cinausero M, Galli G, Basile D, Gerratana L, Fasola G, De Braud F, Sant M, Paolini B, Di Cosimo S, Puglisi F. 167PTime to surgery in early breast cancer treated with neoadjuvant chemotherapy. *Ann Oncol.* 2017;28(suppl_5). doi:10.1093/annonc/mdx362.017.

📄 Poster presentation at the 2017 ESMO Annual Meeting.

Puglisi F, Ceppi M, Gerratana L, Cognetti F, De Placido S, Bruzzi P, De Laurentiis M, Bisagni G, Cavazzini G, Durando A, Turletti A, Valle E, Montemurro F, Barni S, Ardizzoni A, Colantuoni G, Gamucci T, Del Mastro L. 171PComposite index of risk shows that benefit from adjuvant dose dense chemotherapy is not confined to triple negative breast cancer. *Ann Oncol.* 2017;28(suppl_5). doi:10.1093/annonc/mdx362.021.

📄 Poster presentation at the 2017 ESMO Annual Meeting.

Gerratana L, Basile D, Zago S, Vitale MG, Pelizzari G, Bonotto M, Bozza C, Bartoletti M, Fanotto V, Lisanti C, Cinausero M, Barban S, Lera M, Venuti I, Mansutti M, Minisini AM, Fasola G, Curcio F. 199PNeutrophil-to-lymphocyte and lymphocyte-to-monocyte ratios in breast cancer. *Ann Oncol.* 2017;28(suppl_5):272. doi:10.1093/annonc/mdx362.049.

📄 Poster presentation at the 2017 ESMO Annual Meeting.

Bartoletti M, Gerratana L, Zago S, Basile D, Vitale MG, Pelizzari G, Bonotto M, Bozza C, Fanotto V, Lisanti C, Cinausero M, Barban S, Lera M, Venuti I, Mansutti M, Minisini AM, Fasola G, Curcio F, Puglisi F. 287PNeutrophil-to-lymphocyte ratio in metastatic breast cancer: Association with clinico-pathological features and outcome. *Ann Oncol.* 2017;28(suppl_5). doi:10.1093/annonc/mdx365.050.

📄 Poster presentation at the 2017 ESMO Annual Meeting.

Ongaro E, De Maglio G, Gerratana L, Bonotto M, Garattini SK, Basile D, Cattaneo M, Andreotti VJ, Cortiula F, Parnofiello A, Fanotto V, Pizzolitto S, Cardellino GG, Casagrande M, Puglisi F, Aprile G, Pella N, Fasola G. 552PMutational status and metastatic patteRn in a cohort Of ADvanced colorectal cancer (aCRC) patients (pts): The ROAD study. *Ann Oncol.* 2017;28(suppl_5):96. doi:10.1093/annonc/mdx393.078.

📄 Poster presentation at the 2017 ESMO Annual Meeting.

Gerratana L, Lombardi G, De Carlo E, Buoro V, De Maglio G, Marcato R, Isola M, Cattaneo M, Bellu L, Pelizzari G, Gurrieri L, Follador A, Puglisi F, Pizzolitto S, Fasola G, Zagonel V, Rizzato S. A novel MGMT methylation-based prognostic score in patients with glioblastoma. *J Clin Oncol.* 2017;35(15_suppl):2048. doi:10.1200/JCO.2017.35.15_suppl.2048.

📄 Poster presentation at the 2017 ASCO Annual Meeting.

Bonotto M, Gerratana L, Bettini A, Cinausero M, Basile D, Pelizzari G, Vitale MG, Bozza C, Lisanti C, Fanotto V, Bartoletti M, Andretta C, Russo S, Poletto E, Iacono D, Mansutti M, Minisini AM, Fasola G, Puglisi F. Determinants of adjuvant chemotherapy use in small luminal-like breast cancer. *J Clin Oncol.* 2017;35(15_suppl):e12010. doi:10.1200/JCO.2017.35.15_suppl.e12010.

📄 Online publication at the 2017 ASCO Annual Meeting.

Bozza C, Gerratana L, Basile D, Vitale MG, Bartoletti M, Agostinetto E, Russo S, Bonotto M, Cinausero M, Fanotto V, Pelizzari G, Lisanti C, Minisini AM, Andretta C, Mansutti M, Poletto E, Iacono D, Sottile R, Fasola G, Puglisi F. Preliminary results from CAMEO-PRO study: Complementary and alternative medicine in oncology—Physicians inform oncological patients. *J Clin Oncol.* 2017;35(15_suppl):e21632. doi:10.1200/JCO.2017.35.15_suppl.e21632.

📄 Online publication at the 2017 ASCO Annual Meeting.

De Carlo E, Gerratana L, Cinausero M, Vitale MG, Buoro V, Bonotto M, Ermacora P, Sacco CSP, Puglisi F, Fasola G. Setting and timing of end-of-life care in cancer patients. *J Clin Oncol.* 2017;35(15_suppl):e21502. doi:10.1200/JCO.2017.35.15_suppl.e21502.

📄 Online publication at the 2017 ASCO Annual Meeting.

Iacono D, Cinausero M, Gerratana L, Vitale MG, Basile D, Angione V, Scott CA, De Maglio G, Poletto E, Moroso S, Pella N, Fasola G, Puglisi F, Minisini AM. Primary cutaneous melanoma in elderly patients: potential prognostic markers. In: *International Congress of the Society for Melanoma Research.* ; 2016. https://www.melanomacongress.com/docs/2016_abstracts.pdf.

📄 Poster presentation at the Society for Melanoma Research 2016 Congress

Angione V, Scott CA, De Maglio G, Iacono D, Gerratana L, Di Loreto C, Minisini AM, Pizzolitto S. Primary cutaneous melanoma in elderly patients: potential prognostic markers.

📄 Oral communication at the 2016 SIAPEC-IAP Meeting.

Jove M, Ferrari L, Gerratana L, Bonotto M, Cinausero M, Puglisi F, Twelves C. Clinical decision making in patients with Metastatic Breast Cancer in the United Kingdom (UK) and Italy. In: *NCRI Cancer Conference.* ; 2016. <http://abstracts.ncri.org.uk/abstract/clinical-decision-making-in-patients-with-metastatic-breast-cancer-in-the-united-kingdom-uk-and-italy/>.

📄 Poster presentation at 2016 NCRI Cancer Conference

Iacono D, Cinausero M, Gerratana L, Angione V, Scott Ca, De Maglio G, et al. Primary cutaneous melanoma in elderly patients: potential prognostic markers

📄 Poster presentation at IMI 2016

Fasola G, Follador A, Barbiero F, Rosolen V, Belvedere O, Grossi F, Rossetto C, Rizzato S, Giavarra M, Gerratana L, Barbone F. Low dose CT scan screening versus empiric surveillance in asbestos exposed subjects: Update of ATOM 002 study. *Ann Oncol.* 2016;27(suppl_6):iv3-iv3. doi:10.1093/annonc/mdw381.02.

Poster discussion at ESMO2016, Copenhagen October 2016

De Carlo E, Gurrieri L, De Maglio G, Gerratana L, Buoro V, Rizzato S, Isola M, Skrap M, Fasola G, Puglisi F, Pizzolitto S. First steps in the definition of a prognostic score based on MGMT methylation status in patients with glioblastoma. *Ann Oncol.* 2016;27(suppl_6):iv111-iv111. doi:10.1093/annonc/mdw367.17.

Poster presentation at ESMO2016, Copenhagen October 2016

Ferrari L, Gerratana L, Jove M, Bonotto M, Cinausero M, Twelves C, Puglisi F. Clinical decision making in patients with metastatic breast cancer in the United Kingdom (UK) and Italy. *Ann Oncol.* 2016;27(suppl_6). doi:10.1093/annonc/mdw365.30.

Poster presentation at ESMO2016, Copenhagen October 2016

De Carlo E, Gurrieri L, De Maglio G, Gerratana L, Buoro V, Rizzato S, Follador A, Giavarra M, Isola M, Skrap M, Fasola G, Puglisi F, Pizzolitto S. S15Towards the definition of a prognostic score based on MGMT methylation status in patients with glioblastoma: do not lose the forest looking at the tree. *Ann Oncol.* 2016;27(suppl_4):iv111-iv111. doi:10.1093/annonc/mdw345.15.

Poster presentation at the 2016 AIOM Annual Meeting.

Buoro V, De Carlo E, Gerratana L, Giavarra M, Rizzato S, Rossetto C, Macerelli M, Poletto E, Cattaneo M, Pelizzari G, Mansutti M, Aprile G, Follador A, Puglisi F, Fasola G. A37Lung cancer patients and unplanned presentations to hospital: insights from a single institution experience. *Ann Oncol.* 2016;27(suppl_4):iv14-iv14. doi:10.1093/annonc/mdw332.37.

Poster presentation at the 2016 AIOM Annual Meeting.

Fasola G, Follador A, Barbiero F, Rosolen V, Belvedere O, Grossi F, Rossetto C, Rizzato S, Giavarra M, Gerratana L, Barbone F. A02*Low dose computed tomography scan (LDCT) screening versus empiric surveillance in asbestos exposed subjects: an update from the ATOM002 study. *Ann Oncol.* 2016;27(suppl_4):iv3-iv3. doi:10.1093/annonc/mdw332.02.

Oral communication at the 2016 AIOM Annual Meeting.

Ferrari L, Gerratana L, Jove M, Bonotto M, Cinausero M, Iacono D, Fontanella C, Bozza C, Fanotto V, Basile D, Pelizzari G, Vitale MG, Minisini A, Mansutti M, Russo S, Andretta C, Fasola G, Puglisi F, Twelves C. F15Treatment strategies in patients with Metastatic Breast Cancer: real-world practice in the United Kingdom (UK) and Italy. *Ann Oncol.* 2016;27(suppl_4):iv63-iv63. doi:10.1093/annonc/mdw337.15.

Poster presentation at the 2016 AIOM Annual Meeting.

Cinausero M, Gerratana L, Bonotto M, Iacono D, Bozza C, Basile D, Pelizzari G, Vitale MG, Fontanella C, Fanotto V, Andretta C, Minisini AM, Moroso S, Poletto E, Russo S, Mansutti M, Fasola G, Puglisi F. F14Last-line treatment of luminal metastatic breast cancer: which factors influence the therapeutic choice? *Ann Oncol.* 2016;27(suppl_4):iv63-iv63. doi:10.1093/annonc/mdw337.14.

Poster presentation at the 2016 AIOM Annual Meeting.

Ongaro E, Bonotto M, Gerratana L, Casagrande M, Ferrari L, Iacono D, Garattini SK, Fanotto V, Basile D, Cattaneo M, Rihawi K, Giovannoni M, Pella N, Ermacora P, Cardellino GG, Aprile G, Fasola G. D10May mutational status influence the metastatic pattern of colorectal cancer patients? *Ann Oncol.* 2016;27(suppl_4):iv42-iv42. doi:10.1093/annonc/mdw335.10.

Poster presentation at the 2016 AIOM Annual Meeting.

De Carlo E, Buoro V, Gerratana L, Giavarra M, Rizzato S, Rossetto C, Macerelli M, Cattaneo M, Pelizzari G, Mansutti M, Aprile G, Follador A, Puglisi F, Fasola G. Risk of unplanned presentations and hospital admission in lung cancer patients: Insights from the experience of a single institution. *J Clin Oncol.* 2016;34(15_suppl):e21601. doi:10.1200/JCO.2016.34.15_suppl.e21601.

Online publication at the 2016 ASCO Annual Meeting.

Gerratana L, Toffoletto B, Bulfoni M, Cesselli D, Beltrami AP, Di Loreto C, Bonotto M, Cinausero M, Isola M, Marzinotto S, Minisini AM, Sottile R, Mansutti M, Fasola G, Puglisi F. Exploring and characterizing circulating exosomes in metastatic breast cancer patients. *Eur J Cancer.* 2016;57(2 supplement):S19-S153. doi:10.1016/S0959-8049(16)31962-1.

Poster presentation at EBCC2016, Amsterdam March 2016

- Gerratana L, Bulfoni M, Beltrami AP, Di Loreto C, Bonotto M, Cinausero M, Isola M, Toffoletto B, Marzinotto S, Minisini AM, Sottile R, Banzi M, Peruzzi E, Mansutti M, Fasola G, Puglisi F, Cesselli D. 1890 Look up the meaning of distinct circulating tumor cells in metastatic breast cancer. *Eur J Cancer*. 2015;51:S296. doi:10.1016/S0959-8049(16)30840-1.
 Poster presentation at ECC2015, Vienna October 2015
- Bonotto M, Gerratana L, Arpino G, Di Maio M, De Angelis C, Iacono D, Cinausero M, Milano M, Gargiulo P, Fontanella C, Bozza C, Moroso S, Minisini AM, Mansutti M, Fasola G, De Placido S, Puglisi F. 1864 Chemotherapy versus endocrine therapy as first line treatment in patients with luminal-like metastatic breast cancer. Impact on survival. *Eur J Cancer*. 2015;51:S286-S287. doi:10.1016/S0959-8049(16)30814-0.
 Poster presentation at ECC2015, Vienna October 2015
- Cinausero M, Gerratana L, Iacono D, Bonotto M, Bozza C, Bolzonello S, Fanotto V, Poletto E, Fontanella C, Guardascione M, Minisini AM, Russo S, Andreetta C, Moroso S, Sottile R, Mansutti M, Fasola G, Puglisi F. 1860 Last-line treatment of advanced breast cancer: Which clinical characteristics may predict the outcome? *Eur J Cancer*. 2015;51:S285. doi:10.1016/S0959-8049(16)30810-3.
 Poster presentation at ECC2015, Vienna October 2015
- Fontanella C, Fanotto V, De Carlo E, Iacono D, Bozza C, Bonotto M, Cinausero M, Gerratana L, Guardascione M, Russo S, Andreetta C, Moroso S, Minisini AM, Mansutti M, Aprile G, Fasola G, Puglisi F. 1227 Risk of unplanned presentations and hospital admission of breast cancer outpatients. *Eur J Cancer*. 2015;51(suppl 6):S182. doi:10.1016/S0959-8049(16)30531-7.
 Poster presentation at ECC2015, Vienna October 2015
- Moroso S, Bonotto M, Gerratana L, Arpino G, De Angelis C, Iacono D, Cinausero M, Milano M, Gargiulo P, Fontanella C, Bozza C, Fanotto V, De Carlo E, Guardascione M, Russo S, Andreetta C, Minisini AM, Mansutti M, Fasola G, De Placido S, Puglisi F. A03*Luminal-like metastatic breast cancer: which is the room of endocrine maintenance therapy after first line chemotherapy? *Ann Oncol*. 2015;26(suppl 6):vi3.3-vi4. doi:10.1093/annonc/mdv336.03.
 Oral communication at the 2015 AIOM Annual Meeting.
- Bulfoni M, Gerratana L, Puglisi F, Beltrami AP, Di Loreto C, Bonotto M, Cinausero M, Bozza C, Isola M, Toffoletto B, Marzinotto S, Minisini AM, Sottile R, Banzi M, Peruzzi E, Mansutti M, Fasola G, Cesselli D. A14CTC subpopulations in metastatic breast cancer. *Ann Oncol*. 2015;26(suppl 6):vi7.2-vi7. doi:10.1093/annonc/mdv336.14.
 Poster presentation at the 2015 AIOM Annual Meeting.
- Gerratana L, Toffoletto B, Bulfoni M, Cesselli D, Beltrami AP, Di Loreto C, Bonotto M, Cinausero M, Isola M, Marzinotto S, Minisini AM, Sottile R, Mansutti M, Fasola G, Puglisi F. A37Metastatic breast cancer and circulating exosomes. Hints from an exploratory analysis. *Ann Oncol*. 2015;26(suppl 6):vi14.3-vi14. doi:10.1093/annonc/mdv336.37.
 Poster presentation at the 2015 AIOM Annual Meeting.
- Bonotto M, Gerratana L, Arpino G, Di Maio M, De Angelis C, Iacono D, Cinausero M, Milano M, Gargiulo P, Fontanella C, Bozza C, Moroso S, Minisini AM, Mansutti M, Fasola G, De Placido S, Puglisi F. A17First line treatment in patients with luminal-like metastatic breast cancer: a propensity score-matched analysis. *Ann Oncol*. 2015;26(suppl 6):vi8.2-vi8. doi:10.1093/annonc/mdv336.17.
 Poster presentation at the 2015 AIOM Annual Meeting.
- Cinausero M, Gerratana L, Iacono D, Bonotto M, Bozza C, Bolzonello S, Fanotto V, Poletto E, Fontanella C, Guardascione M, Minisini AM, Russo S, Andreetta C, Moroso S, Mansutti M, Fasola G, Puglisi F. A07Last-line treatment of advanced breast cancer: outcome measures and prognostic factors. *Ann Oncol*. 2015;26(suppl 6):vi5.1-vi5. doi:10.1093/annonc/mdv336.07.
 Poster presentation at the 2015 AIOM Annual Meeting.
- Bolzonello S, Poletto E, Gerratana L, Bonotto M, Cinausero M, Fanotto V, Alessandra B, De Carlo E, Ermacora P, Pisa FE, Puglisi F, Fasola G. N03Active treatment near the end-of-life in metastatic cancer patients. *Ann Oncol*. 2015;26(suppl 6):vi.156-vi. doi:10.1093/annonc/mdv346.03.
 Poster presentation at the 2015 AIOM Annual Meeting.
- De Carlo E, Gerratana L, Gurrieri L, De Maglio G, Rizzato S, Follador A, Pizzolotto S, Buoro V, Skrap M, Pisa F, Puglisi F, Fasola G. R14Prognostic value of MGMT gene promoter methylation evaluated on ten CpG sites in patients with glioblastoma multiforme: a single-institution experience. *Ann Oncol*. 2015;26(suppl 6):vi.229-vi. doi:10.1093/annonc/mdv348.14.
 Poster presentation at the 2015 AIOM Annual Meeting.

Iacono D, Cinausero M, Gerratana L, Poletto E, Moroso S, Pella N, Puglisi F, Fasola G, Minisini AM. B04Primary cutaneous melanoma in elderly patients: analyses and considerations from a retrospective observational study. *Ann Oncol.* 2015;26(suppl 6):vi27.1-vi27. doi:10.1093/annonc/mdv337.04.

📄 Poster presentation at the 2015 AIOM Annual Meeting.

Fontanella C, Fanotto V, De Carlo E, Iacono D, Bozza C, Bonotto M, Cinausero M, Gerratana L, Guardascione M, Rihawi K, Russo S, Andretta C, Minisini AM, Moroso S, Mansutti M, Sottile R, Aprile G, Fasola G, Puglisi F. A10Risk of unplanned presentations and hospital admission of metastatic breast cancer outpatients. *Ann Oncol.* 2015;26(suppl 6):vi6.1-vi6. doi:10.1093/annonc/mdv336.10.

📄 Poster presentation at the 2015 AIOM Annual Meeting.

Bozza C, Fontanella C, Fanotto V, De Carlo E, Iacono D, Bonotto M, Cinausero M, Gerratana L, Guardascione M, Rihawi K, Russo S, Andretta C, Minisini AM, Moroso S, Mansutti M, Aprile G, Fasola G, Puglisi F. A11Unplanned hospital admission of early breast cancer outpatients treated with adjuvant chemotherapy. *Ann Oncol.* 2015;26(suppl 6):vi6.2-vi6. doi:10.1093/annonc/mdv336.11.

📄 Poster presentation at the 2015 AIOM Annual Meeting.

Cardellino GG, Bonotto M, Rihawi K, Gerratana L, Casagrande M, Ferrari L, Ongaro E, Iacono D, Garattini SK, Fanotto V, Iaiza E, Ermacora P, Giovannoni M, Pella N, Puglisi F, Aprile G, Fasola G. E37Pattern of metastasis and outcome in patients with colorectal cancer: *Ann Oncol.* 2015;26(suppl 6):vi47.3-vi47. doi:10.1093/annonc/mdv340.37.

📄 Poster presentation at the 2015 AIOM Annual Meeting.

Fontanella C, Fanotto V, Gerratana L, Bonotto M, Cinausero M, Bozza C, Iacono D, Russo S, Andretta C, Minisini A, Moroso S, Mansutti M, Fasola G, Puglisi F. Abstract P2-08-06: Usefulness of the pre-treatment neutrophil-to-lymphocyte ratio in predicting first-line progression free-survival in triple-negative breast cancer patients. *Cancer Res.* 2016;76(4 Supplement):P2-08-06-P2-08-06. doi:10.1158/1538-7445.SABCS15-P2-08-06.

📄 Poster presentation at the 2015 SABCS Annual Meeting.

Iacono D, Cinausero M, Gerratana L, Poletto E, Moroso S, Pella N, et al. Melanoma cutaneo primitivo nei pazienti anziani: analisi e considerazioni di uno studio osservazionale retrospettivo.

📄 Poster presentation at the 2015 IMI Annual Meeting.

Gerratana L, Bonotto M, Cinausero M, Iacono D, Fasola G, Puglisi F. Endocrine maintenance therapy in luminal breast cancer. *J Clin Oncol.* 2015;33(15_suppl):e11578. doi:10.1200/jco.2015.33.15_suppl.e11578.

📄 Online publication at the 2015 ASCO Annual Meeting.

Bonotto M, Gerratana L, De Angelis C, Arpino G, Iacono D, Cinausero M, Fasola G, Puglisi F. Endocrine therapy and chemotherapy in luminal metastatic breast cancer. *J Clin Oncol.* 2015;33(15_suppl):e11573. doi:10.1200/jco.2015.33.15_suppl.e11573.

📄 Online publication at the 2015 ASCO Annual Meeting.

Bolzonello S, Gerratana L, Poletto E, Bonotto M, Fanotto V, Cinausero M, Bernardis A, Pisa FE, Fasola G. Treatment during the last month of life in advanced cancer patients. *J Clin Oncol.* 2015;33(15_suppl):e17649. doi:10.1200/jco.2015.33.15_suppl.e17649.

📄 Online publication at the 2015 ASCO Annual Meeting.

Gerratana L, Fanotto V, Bonotto M, Bolzonello S, Andretta C, Moroso S, Pascoletti G, Fasola G, Puglisi F. Pattern of metastatic spread and prognosis of breast cancer biologic subtypes. *J Clin Oncol.* 2014;32(15_suppl):e12532. doi:10.1200/jco.2014.32.15_suppl.e12532.

📄 Online publication at the 2014 ASCO Annual Meeting.

Gerratana L, Fanotto V, Bonotto M, Bolzonello S, Andretta C, Moroso S, Pascoletti G, Fasola G, Puglisi F. Pattern of metastatic spread and prognosis of breast cancer biologic subtypes. *J Clin Oncol.* 2014;32(15_suppl):e12532. doi:10.1200/jco.2014.32.15_suppl.e12532.

📄 Online publication at the 2014 ASCO Annual Meeting.

Bonotto M, Gerratana L, Mansutti M, Moroso S, Russo S, Iacono D, Minisini A, Fasola G, Puglisi F. Advanced luminal breast cancer: Who receives chemotherapy as first-line systemic treatment? *J Clin Oncol.* 2014;32(15_suppl):e11524. doi:10.1200/jco.2014.32.15_suppl.e11524.

📄 Online publication at the 2014 ASCO Annual Meeting.

Gerratana L, Cinausero M, Bonotto M, Poletto E, Iacono D, Bolzonello S, Bozza C, Bernardis A, Guardascione M, Fontanella C, Pascoletti G, Minisini AM, Russo S, Andretta C, Moroso S, Sottile R, Mansutti M, Fasola G, Puglisi F. Outcome after last-line treatment in metastatic breast cancer. *Tumori*. 2014;15(1_suppl):S13.

📄 Poster presentation at the 2014 AIOM Annual Meeting.

Fontanella C, Fanotto V, Gerratana L, Bolzonello S, Poletto E, Guardascione M, Iacono D, Bozza C, Bonotto M, Cinausero M, Moroso S, Russo S, Andretta C, Minisini AM, Pascoletti G, Sottile R, Mansutti M, Fasola G, Puglisi F. Body mass index and tolerability of first-line taxane-based chemotherapy in metastatic breast cancer patients. *Tumori*. 2014;15(1_suppl):S20.

📄 Poster presentation at the 2014 AIOM Annual Meeting.

Fanotto V, Gerratana L, Bonotto M, Bolzonello S, Iacono D, Bozza C, Poletto E, Cinausero M, Fontanella C, Guardascione M, Andretta C, Russo S, Minisini AM, Moroso S, Pascoletti G, Sottile R, Mansutti M, Fasola G, Puglisi F. Breast cancer biologic subtypes: pattern of metastatic spread and measures of outcome. *Tumori*. 2014;15(1_suppl):S14.

📄 Poster presentation at the 2014 AIOM Annual Meeting.

Bonotto M, Gerratana L, Iacono D, Moroso S, Poletto E, Cinausero M, Bozza C, Bolzonello S, Fontanella C, Guardascione M, Fanotto V, Russo S, Andretta C, Minisini AM, Pascoletti G, Sottile R, Mansutti M, Fasola G, Puglisi F. First-line treatment of advanced luminal breast cancer: chemotherapy or endocrine therapy? *Tumori*. 2014;15(1_suppl):S13.

📄 Poster presentation at the 2014 AIOM Annual Meeting.

Russo S, Gerratana L, Cinausero M, Bozza C, Iacono D, Sottile R, Fasola G, Puglisi F. Factors affecting patient's perception of anticancer treatments side-effects: an observational study. *Support Care Cancer*. 2013;21(S1):1-301. doi:10.1007/s00520-013-1798-3.

📄 Online publication at the 2013 MASCC Annual Meeting

Bonotto M, Gerratana L, Minisini A, Poletto E, Russo S, Andretta C, Mansutti M, Fasola G, Puglisi F. Prediction of benefit from treatment beyond the first line in patients with metastatic breast cancer (MBC). *J Clin Oncol*. 2013;31(15_suppl):e11565. doi:10.1200/jco.2013.31.15_suppl.e11565.

📄 Online publication at the 2013 ASCO Annual Meeting.

Sottile R, Bonotto M, Gerratana L, Bozza C, Poletto E, Fontanella C, Iacono D, Moroso S, Andretta C, Russo S, Minisini AM, Mansutti M, Fasola G, Puglisi F. Measures of outcome versus endpoints for drug development in metastatic breast cancer: hints from a single institution analysis. *Tumori*. 2013;14(1_suppl):S122.

📄 Poster presentation at the 2013 AIOM Annual Meeting.

Iacono D, Russo S, Bozza C, Gerratana L, Cinausero M, Bonotto M, Bolzonello S, Guardascione M, Pascoletti G, Sottile R, Fasola G, Puglisi F. Patient's perception of side effects of anticancer treatment: an observational study. *Tumori*. 2013;14(1_suppl):S49.

📄 Poster presentation at the 2013 AIOM Annual Meeting.

Gerratana L, Ongaro E, Giangreco M, Di Carla L, Poletto E, Bozza C, Bonotto M, Russo S, Andretta C, Minisini AM, Mansutti M, Sottile R, Fasola G, Puglisi F. Changes in the ki-67 expression between primary breast cancer and paired metastases: understanding the prognostic effect of discordance. *Tumori*. 2013;14(1_suppl):S124.

📄 Poster presentation at the 2013 AIOM Annual Meeting.

Bonotto M, Gerratana L, Pisa F, Giangreco M, Poletto E, Iacono D, Andretta C, Russo S, Minisini A, Mansutti M, Sottile R, Fasola G, Puglisi F. Treatment of metastatic breast cancer: is progression-free survival after first-line predictive of benefit from second and later lines? *Tumori*. 2013;14(1_suppl):S117.

📄 Oral communication at the 2013 AIOM Annual Meeting.

Bolzonello S, Bonotto M, Gerratana L, Pisa FE, Giangreco M, Sottile R, Russo S, Andretta C, Minisini AM, Poletto E, Bozza C, Iacono D, Guardascione Michela, Fontanella C, Moroso S, Pascoletti G, Mansutti M, Fasola G, Puglisi F. Prognostic factors across different lines of therapy for metastatic breast cancer. *Tumori*. 2013;14(1_suppl):S120.

📄 Poster presentation at the 2013 AIOM Annual Meeting.

Andretta C, Iacono D, Poletto E, Fontanella C, Minisini A, Russo S, Bozza C, Bonotto M, Gerratana L, Sottile R, Moroso S, Pascoletti G, Mansutti M, Fasola G, Puglisi F. Prognostic value of body mass index in metastatic breast cancer. *Tumori*. 2013;14(1_suppl):S140.

📄 Poster presentation at the 2013 AIOM Annual Meeting.

Fontanella C, Bonotto M, Driol P, Valent F, Gerratana L, Russo S, Andreetta C, Minisini A, Mansutti M, Sottile R, Fasola G, Puglisi F. Tailored endpoints: A proposal for design of future clinical trials in metastatic breast cancer (MBC). *J Clin Oncol.* 2012;30(15_suppl):e13058. doi:10.1200/jco.2012.30.15_suppl.e13058.

📄 Online publication at the 2012 ASCO Annual Meeting.

Driol P, Bonotto M, Fontanella C, Gerratana L, Valent F, Russo S, Andreetta C, Minisini A, Sottile R, Mansutti M, Fasola G, Puglisi F. Endocrine therapy in patients with metastatic breast cancers (MBC): Prognosis and measures of outcome. *J Clin Oncol.* 2012;30(15_suppl):e13070. doi:10.1200/jco.2012.30.15_suppl.e13070.

📄 Online publication at the 2012 ASCO Annual Meeting.

Andreetta C, Driol P, Bonotto M, Gerratana L, Valent F, Russo S, Minisini A, Pascoletti G, Moroso S, Sottile R, Mansutti M, Fasola G, Puglisi F. Association of body mass index and outcome in advanced breast cancer. *J Clin Oncol.* 2012;30(15_suppl):1044. doi:10.1200/jco.2012.30.15_suppl.1044.

📄 Poster presentation at the 2012 ASCO Annual Meeting.

PRIVACY STATEMENT

I consent to the use of my personal data, in accordance with the current law (General Data Protection Regulation, GDPR Regulation EU 2016/679)